Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A sub(2) (Lp-PLA sub(2)) Inhibitor [ super(18)F]GSK2647544 in Healthy Male Subjects

GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A sub(2) (Lp-PLA sub(2)), which was in development as a potential treatment for Alzheimer's disease (AD). In order to refine therapeutic dose predictions and confirm brain penetration, a radiolabelled form of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular imaging and biology 2017-02, Vol.19 (1), p.153-161
Hauptverfasser: Huiban, Mickael, Coello, Christopher, Wu, Kai, Xu, Yanmei, Lewis, Yvonne, Brown, Andrew P, Buraglio, Mauro, Guan, Chenbing, Shabbir, Shaila, Fong, Regan, Passchier, Jan, Rabiner, Eugenii A, Lockhart, Andrew
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A sub(2) (Lp-PLA sub(2)), which was in development as a potential treatment for Alzheimer's disease (AD). In order to refine therapeutic dose predictions and confirm brain penetration, a radiolabelled form of the inhibitor, [ super(18)F]GSK2647544, was manufactured for use in a positron emission tomography (PET) biodistribution study. [ super(18)F]GSK2647544 was produced using a novel, copper iodide (Cu(I)) mediated, [ super(18)F]trifluoromethylation methodology. Healthy male subjects (n=4, age range 34-42) received an oral dose of unlabelled GSK2647544 (100 mg) and after 2 h an intravenous (iv) injection of [ super(18)F]GSK2647544 (average injected activity and mass were 106 plus or minus 47 MBq and 179 plus or minus 55 mu g, respectively) followed by dynamic PET scans for 120 min. Defined regions of interest (ROI) throughout the brain were used to obtain regional time-activity curves (TACs) and compartmental modelling analysis used to estimate the primary outcome measure, whole brain volume of distribution (V sub(T)). Secondary PK and safety endpoints were also recorded. PET dynamic data were successfully obtained from all four subjects and there were no clinically significant variations of the safety endpoints. Inspection of the TACs indicated a relatively homogenous uptake of [ super(18)F]GSK2647544 across all the ROIs examined. The mean whole brain V sub(T) was 0.56 (95 % CI, 0.41-0.72). Secondary PK parameters, C sub(max) (geometric mean) and T sub(max) (median), were 354 ng/ml and 1.4 h, respectively. Metabolism of GSK2647544 was relatively consistent across subjects, with 20-40 % of the parent compound [ super(18)F]GSK2647544 present after 120 min. The study provides evidence that GSK2647544 is able to cross the blood brain barrier in healthy male subjects leading to a measurable brain exposure. The administered doses of GSK2647544 were well tolerated. Exploratory modelling suggested that a twice-daily dose of 102 mg, at steady state, would provide ~80 % trough inhibition of brain Lp-PLA sub(2) activity. Clintrials.gov: NCT01924858.
ISSN:1536-1632
1860-2002
DOI:10.1007/s11307-016-0982-5